Resultats de la cerca - Dirk Müller‐Wieland

Refinar resultats
  1. 1
    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation

    Obesity Associated with a Mutation in a Genetic Regulator of Adipocyte Differentiation per Michael Ristow, Dirk Müller‐Wieland, A. Pfeiffer, Wilhelm Krone, C. Ronald Kahn

    Publicat 1998
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo

    Insulin-activated Erk-mitogen-activated Protein Kinases Phosphorylate Sterol Regulatory Element-binding Protein-2 at Serine Residues 432 and 455 in Vivo per Jörg Kotzka, Stefan Lehr, Gunther Roth, Haluk Avci, Birgit Knebel, Dirk Müller‐Wieland

    Publicat 2004
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I

    SREBP-1 Mediates Activation of the Low Density Lipoprotein Receptor Promoter by Insulin and Insulin-like Growth Factor-I per Rüdiger Streicher, Jörg Kotzka, Dirk Müller‐Wieland, Gerhard Siemeister, Martina Munck, Haluk Avci, Wilhelm Krone

    Publicat 1996
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis

    Five cases with central diabetes insipidus and hypogonadism as first presentation of neurosarcoidosis per Catharina Bullmann, Michael Faust, Anne Lisbeth Hoffmann, Christina Heppner, F. Jockenhövel, Dirk Müller‐Wieland, W Krone

    Publicat 2000
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus per Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Ruediger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass

    Liver-Specific Expression of Transcriptionally Active SREBP-1c Is Associated with Fatty Liver and Increased Visceral Fat Mass per Birgit Knebel, Jutta Haas, Sonja Hartwig, Sylvia Jacob, Cornelia Köllmer, Ulrike Nitzgen, Dirk Müller‐Wieland, Jörg Kotzka

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade

    Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade per Jörg Kotzka, Dirk Müller‐Wieland, Gunther Roth, L. Kremer, Martina Munck, Sandra Schürmann, Birgit Knebel, Wilhelm Krone

    Publicat 2000
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity

    Preventing Phosphorylation of Sterol Regulatory Element-Binding Protein 1a by MAP-Kinases Protects Mice from Fatty Liver and Visceral Obesity per Jörg Kotzka, Birgit Knebel, Jutta Haas, L. Kremer, Sylvia Jacob, Sonja Hartwig, Ulrike Nitzgen, Dirk Müller‐Wieland

    Publicat 2012
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Definition, Classification and Diagnosis of Diabetes Mellitus

    Definition, Classification and Diagnosis of Diabetes Mellitus per Astrid Petersmann, Dirk Müller‐Wieland, Ulrich Müller, Rüdiger Landgraf, Matthias Nauck, Guido Freckmann, Lutz Heinemann, Erwin Schleicher

    Publicat 2019
    Obtenir text complet Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  10. 10
    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro

    MAP Kinases Erk1/2 Phosphorylate Sterol Regulatory Element-binding Protein (SREBP)-1a at Serine 117 in Vitro per Gunther Roth, Jörg Kotzka, L. Kremer, Stefan Lehr, Christiane Lohaus, Helmut E. Meyer, Wilhelm Krone, Dirk Müller‐Wieland

    Publicat 2000
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit

    Clinical course of COVID-19 patients needing supplemental oxygen outside the intensive care unit per Ayham Daher, Paul Balfanz, Maria Aetou, Bojan Hartmann, Dirk Müller‐Wieland, Tobias Müller, Nikolaus Marx, Michael Dreher, Christian Cornélissen

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae

    Follow up of patients with severe coronavirus disease 2019 (COVID-19): Pulmonary and extrapulmonary disease sequelae per Ayham Daher, Paul Balfanz, Christian Cornélissen, Annegret Müller, Ingmar Bergs, Nikolaus Marx, Dirk Müller‐Wieland, Bojan Hartmann, Michael Dreher, Tobias Müller

    Publicat 2020
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Austrian</scp> diabetes registry

    <scp>L</scp>ow‐density lipoprotein cholesterol and non‐high‐density lipoprotein cholesterol in type 1 diabetes and type 2 diabetes: Lipid goal attainment in a large <scp>German–Aus... per Julia Brandts, Sascha R. Tittel, Peter Bramlage, Thomas Danne, Johanna Brix, Stefan Zimny, Christoph H. J. Heyer, Reinhard W. Holl, Dirk Müller‐Wieland

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia

    Efficacy and Safety of Ezetimibe Added to Atorvastatin Versus Atorvastatin Uptitration or Switching to Rosuvastatin in Patients With Primary Hypercholesterolemia per Harold Bays, Maurizio Averna, Claudio Majul, Dirk Müller‐Wieland, Annamaria De Pellegrin, Hilde Giezek, Raymond Lee, Robert S. Lowe, Philippe Brudi, Joseph Triscari, Michel Farnier

    Publicat 2013
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Therapy of Type 2 Diabetes

    Therapy of Type 2 Diabetes per Rüdiger Landgraf, Jens Aberle, Andreas L. Birkenfeld, Baptist Gallwitz, Monika Kellerer, Harald Klein, Dirk Müller‐Wieland, Michael A. Nauck, Hans‐Martin Reuter, Erhard Siegel

    Publicat 2019
    Obtenir text complet
    Revisão
    Afegir a favorits
    Guardat en:
  16. 16
    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2

    Phosphorylation of sterol regulatory element-binding protein (SREBP)-1c by p38 kinases, ERK and JNK influences lipid metabolism and the secretome of human liver cell line HepG2 per Birgit Knebel, Stefan Lehr, Sonja Hartwig, Jutta Haas, Gernot Kaber, Hans-Dieter Dicken, Franciscus Susanto, Lothar Bohne, Sylvia Jacob, Ulrike Nitzgen, Waltraud Paßlack, Dirk Müller‐Wieland, Jörg Kotzka

    Publicat 2014
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes

    Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes per Dirk Müller‐Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo García‐Sánchez, Raisa Kurlyandskaya, C. David Sjöström, Stephan Jacob, Jochen Seufert, Nalina Dronamraju, Katalin Csomós

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies

    No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies per Helen M. Colhoun, Henry N. Ginsberg, Jennifer G. Robinson, Lawrence A. Leiter, Dirk Müller‐Wieland, Robert R. Henry, Bertrand Cariou, Marie T. Baccara‐Dinet, Robert Pordy, Laurence Merlet, Robert H. Eckel

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial

    Efficacy and safety of alirocumab in insulin‐treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The <scp>ODYSSEY DM‐INSULIN</scp> randomized trial per Lawrence A. Leiter, Bertrand Cariou, Dirk Müller‐Wieland, Helen M. Colhoun, Stefano Del Prato, Francisco J. Tinahones, Kausik K. Ray, Maja Bujas‐Bobanovic, Catherine Domenger, Jonas Mandel, Rita Samuel, Robert R. Henry

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial

    Alirocumab vs usual lipid‐lowering care as add‐on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM‐DYSLIPIDEMIA randomized trial per Kausik K. Ray, Lawrence A. Leiter, Dirk Müller‐Wieland, Bertrand Cariou, Helen M. Colhoun, Robert R. Henry, Francisco J. Tinahones, Maja Bujas‐Bobanovic, Catherine Domenger, Alexia Letierce, Rita Samuel, Stefano Del Prato

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: